A clinical observational study for Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19)

Observational study of Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ITMCTR

Registry ID

ITMCTR2000002978

Enrollment

Unknown

Registered

2020-02-07

Start date

2020-02-07

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

Experimental group:Xinguan-2 formula+Standard treatment

Control group:Standard treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet the diagnostic criteria of suspected cases of pneumonia caused by novel coronavirus infection.

Exclusion criteria

Exclusion criteria: An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients in Xin-Guan-2 formula.

Design outcomes

Primary

Measure	Time frame
Time to completely antipyretic time:completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Main symptom relief/disappearance time: defined as the days when the three main symptoms of fever, cough and shortness of breath all remission/disappear.;	—

Secondary

Measure	Time frame
Liver and kidney function;The incidence of medical complications during isolation;Length of hospital stay;C-reactive protein;Proportion of good clinical response patients;Routine blood test;	—

Countries

China

Contacts

Public ContactZhang Zhongde

Guangdong Provincial Hospital of Chinese Medicine

doctorzzd99@163.com+86 13903076359

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026